Palladium‐Catalyzed Decarbonylative Difluoromethylation of Acid Chlorides at Room Temperature
作者:Fei Pan、Gregory B. Boursalian、Tobias Ritter
DOI:10.1002/anie.201811139
日期:2018.12.17
Methods for the direct synthesis of difluoromethylated arenes are sparse, despite the importance of the difluoromethyl group in medical, agro‐, and materials chemistry. A palladium‐catalyzed decarbonylative cross‐coupling reaction of acid chlorides with a difluoromethyl zinc reagent is achieved to access difluoromethylated compounds. The transformation proceeds at roomtemperature and shows broad functional
Novel compounds of the formula I
in which
X, Y, R1, R2 and R3 are as defined in Patent Claim 1
are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders.
Pramipexole Derivatives as Potent and Selective Dopamine D<sub>3</sub>Receptor Agonists with Improved Human Microsomal Stability
作者:Jianyong Chen、Cheng Jiang、Beth Levant、Xiaoqin Li、Ting Zhao、Bo Wen、Ruijuan Luo、Duxin Sun、Shaomeng Wang
DOI:10.1002/cmdc.201402398
日期:2014.12
selective agonists of the dopamine‐3 (D3) receptor. A number of these new compounds bind to the D3 receptor with sub‐nanomolar affinity and show excellent selectivity (>10 000) for the D3 receptor over the D1 and D2 receptors. For example, compound 23 (N‐(cis‐3‐(2‐(((S)‐2‐amino‐4,5,6,7‐tetrahydrobenzo[d]thiazol‐6‐yl)(propyl)amino)ethyl)‐3‐hydroxycyclobutyl)‐3‐(5‐methyl‐1,2,4‐oxadiazol‐3‐yl)benzamide)
在此,我们报告了一系列新的普拉克索衍生物作为多巴胺-3 (D 3 ) 受体的高效选择性激动剂的合成和评估。许多这些新的化合物结合至d的3具有亚纳摩尔亲和力受体并显示了d优异的选择性(> 10 000)3受体在d 1和d 2受体。例如,化合物23 ( N -( cis -3-(2-(( ( S )-2-amino-4,5,6,7-tetrahydrobenzo[ d ]thiazol-6-yl)(prop)amino)ethyl )-3-羟基环丁基)-3-(5-甲基-1,2,4-恶二唑-3-基)苯甲酰胺)与 D 3受体结合,Ki值为 0.53 n M,并在使用大鼠脑制剂的结合测定中显示对 D 2和 D 1受体的选择性 > 20 000 。它在人肝微粒体中具有极好的稳定性。此外,体外功能测定表明它是人 D 3受体的完全激动剂。
Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom
申请人:Van Quaquebeke Eric
公开号:US20080292585A1
公开(公告)日:2008-11-27
Azonafide derivatives are obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmaceutical compositions for the prevention and treatment of cell proliferative disorders, in particular several forms of Cancer.